Redeye: Orexo - Solid start på 2019

Utvecklingen under Q1 2019 var bra, i linje med våra förväntningar. Vi har uppdaterat våra prognoser och värderingen.

Läs mer och ladda ned analysen:

Börja följ bolag hos Redeye för att direkt få de senaste analyserna inom Tech och Life Science.

Detta är ett pressmeddelande från Redeye - Research Powered Investment Banking.   

Om oss

Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.